372 related articles for article (PubMed ID: 31685745)
1. [Risk of Euglycemic Diabetic Ketoacidosis Due to Low-carbohydrate Diet While Taking Empagliflozin: a Case Report].
Yamamoto M; Ide N; Kitajima S; Obayashi M; Asada K; Matsushima S; Ito M
Yakugaku Zasshi; 2019; 139(11):1479-1483. PubMed ID: 31685745
[TBL] [Abstract][Full Text] [Related]
2. A Case Report: Euglycemic Diabetic Ketoacidosis Presenting as Chest Pain in a Patient on a Low Carbohydrate Diet.
Dorcely B; Nitis J; Schwartzbard A; Newman JD; Goldberg IJ; Sum M
Curr Diabetes Rev; 2021; 17(2):243-246. PubMed ID: 32178617
[TBL] [Abstract][Full Text] [Related]
3. Ketoacidosis Due to Empagliflozin, a Paradigm Shift: Case Report and Review of Literature.
Hernandez-Quiles C; Ramirez-Duque N; Acosta-Delgado D
Curr Diabetes Rev; 2019; 15(4):259-262. PubMed ID: 30047331
[TBL] [Abstract][Full Text] [Related]
4. Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.
Dull RB; Spangler ML; Knezevich EL; Lau BM
J Pharm Pract; 2019 Apr; 32(2):240-243. PubMed ID: 29241389
[TBL] [Abstract][Full Text] [Related]
5. Severe euglycemic diabetic ketoacidosis of multifactorial etiology in a type 2 diabetic patient treated with empagliflozin: case report and literature review.
Sampani E; Sarafidis P; Dimitriadis C; Kasimatis E; Daikidou D; Bantis K; Papanikolaou A; Papagianni A
BMC Nephrol; 2020 Jul; 21(1):276. PubMed ID: 32669085
[TBL] [Abstract][Full Text] [Related]
6. Delayed euDKA Associated With Dapagliflozin After Pancreatitis.
Wu G; Wu S; Tang J; Wu H
Clin Ther; 2023 Jul; 45(7):e167-e170. PubMed ID: 37248092
[TBL] [Abstract][Full Text] [Related]
7. Euglycemic Diabetic Ketoacidosis Associated with Empagliflozin Use in the Course of the SARS-Cov-2 Pandemic.
Ozer O; Yorulmaz G
J Coll Physicians Surg Pak; 2020 Oct; 30(10):110-111. PubMed ID: 33115581
[TBL] [Abstract][Full Text] [Related]
8. Low carbohydrate diet while taking dapagliflozin: A case report and review of literature.
Paul N; Jonklaas J
Diabetes Metab Syndr; 2021; 15(1):361-363. PubMed ID: 33517150
[No Abstract] [Full Text] [Related]
9. Euglycemic Diabetic Ketoacidosis Caused by SGLT2 Inhibitors and a Ketogenic Diet: A Case Series and Review of Literature.
Mistry S; Eschler DC
AACE Clin Case Rep; 2021; 7(1):17-19. PubMed ID: 33851013
[TBL] [Abstract][Full Text] [Related]
10. Diabetic Ketoacidosis in Patients with Type 2 Diabetes on Sodium-Glucose Cotransporter-2 Inhibitors - A Case Series.
Sharma PV; Jobanputra YB; Lewin K; Bagatell S; Lichtstein DM
Rev Recent Clin Trials; 2018; 13(2):156-160. PubMed ID: 29542418
[TBL] [Abstract][Full Text] [Related]
11. A Case of Euglycemic Diabetic Ketoacidosis due to Empagliflozin Use in a Patient with Type 1 Diabetes Mellitus.
Bilgin S; Duman TT; Kurtkulagi O; Yilmaz F; Aktas G
J Coll Physicians Surg Pak; 2022 Jul; 32(7):928-930. PubMed ID: 35795946
[TBL] [Abstract][Full Text] [Related]
12. [Acidosis without marked hyperglycemia : Euglycemic diabetic ketoacidosis associated with SGLT2-Inhibitors].
Valek R; Von der Mark J
Med Klin Intensivmed Notfmed; 2017 Mar; 112(2):145-148. PubMed ID: 27221094
[TBL] [Abstract][Full Text] [Related]
13. Challenges in the Diagnosis of Euglycemic Diabetic Ketoacidosis in a Patient With Multiple Sclerosis Taking a Sodium-Glucose Cotransporter 2 Inhibitor.
Allison R; Goldstein D; Musso MW
J Emerg Med; 2019 Jul; 57(1):e1-e3. PubMed ID: 31027990
[TBL] [Abstract][Full Text] [Related]
14. Case Report: High-Calorie Glucose Infusion and Tight Glycemic Control in Ameliorating Refractory Acidosis of Empagliflozin-Induced Euglycemic Diabetic Ketoacidosis.
Wan Azman SS; Sukor N; Abu Shamsi MY; Ismail I; Kamaruddin NA
Front Endocrinol (Lausanne); 2022; 13():867647. PubMed ID: 35712244
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin (SGLT2-i) induced euglycaemic diabetic ketoacidosis.
Leader R; Cowen J; Rajeev SP
BMJ Case Rep; 2019 Sep; 12(9):. PubMed ID: 31537607
[TBL] [Abstract][Full Text] [Related]
16. [Ketogenic diet as a trigger for diabetic euglycaemic ketoacidosis in a patient under treatment with iSGLT2].
Nubiola A; Ternianov A; Remolins I
Hipertens Riesgo Vasc; 2020; 37(1):39-41. PubMed ID: 31734176
[TBL] [Abstract][Full Text] [Related]
17. Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report.
Kitahara C; Morita S; Kishimoto S; Matsuno S; Uraki S; Takeshima K; Furukawa Y; Inaba H; Iwakura H; Ariyasu H; Furuta H; Nishi M; Akamizu T
J Diabetes Investig; 2021 Apr; 12(4):664-667. PubMed ID: 32686282
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin induced euglycemic diabetic ketoacidosis in a patient undergoing coronary artery bypass graft despite discontinuation of the drug 48 hours prior to the surgery.
Kuchay MS; Mishra SK; Mehta Y
Diabetes Metab Syndr; 2021; 15(3):909-911. PubMed ID: 33915345
[No Abstract] [Full Text] [Related]
19. SGLT2 inhibitors and metformin: Dual antihyperglycemic therapy and the risk of metabolic acidosis in type 2 diabetes.
Donnan K; Segar L
Eur J Pharmacol; 2019 Mar; 846():23-29. PubMed ID: 30639796
[TBL] [Abstract][Full Text] [Related]
20. Empagliflozin-Associated Euglycemic Diabtetic Ketoacidosis.
Soni P; Kumar V; Saradna A; Kupfer Y
Am J Ther; 2018; 25(6):e740-e741. PubMed ID: 29746292
[No Abstract] [Full Text] [Related]
[Next] [New Search]
